Launiainen Terhi, Vuori Erkki, Ojanperä Ilkka
Department of Forensic Medicine, University of Helsinki, P.O. Box 40, 00014, Helsinki, Finland.
Int J Legal Med. 2009 Mar;123(2):109-15. doi: 10.1007/s00414-008-0261-3. Epub 2008 Jun 27.
The prevalence of important adverse drug combinations was studied among the 37,367 cases included in the Finnish post-mortem toxicology database during 2000-2006. The new SFINX interaction database (Swedish, Finnish, INteraction X-referencing) was utilised to identify adverse drug combinations. Consequently, the 24 drugs chosen for the study generated 96 two-compound combinations possessing potentially severe interactions. The total number of hits for the combinations found in the post-mortem database was 267, which accounts for approximately 0.71% of all cases. The potential role of adverse drug interaction (ADI) in these cases was evaluated from the background information and death certificate. The possible ADI cases comprised 23% of all hits and 0.17% of all cases analysed. In cases with a pharmacodynamic mechanism, the most prominent combinations were medicines causing serotonin syndrome or a beta(1)-blocker with verapamil or diltiazem. In cases with a pharmacokinetic mechanism, half of the cases involved digoxin in combination with verapamil. In one third of the possible ADI cases, a forensic pathologist had noted the studied compounds as an underlying or contributing cause of death, although the agents' specific role in ADIs was rarely recognised.
2000年至2006年期间,在芬兰尸检毒理学数据库纳入的37367例病例中,对重要的不良药物组合的流行情况进行了研究。利用新的SFINX相互作用数据库(瑞典语、芬兰语、相互作用交叉引用)来识别不良药物组合。因此,为该研究选择的24种药物产生了96种具有潜在严重相互作用的双化合物组合。在尸检数据库中发现的组合的命中总数为267,约占所有病例的0.71%。根据背景信息和死亡证明对这些病例中药物不良相互作用(ADI)的潜在作用进行了评估。可能的ADI病例占所有命中病例的23%,占所有分析病例的0.17%。在具有药效学机制的病例中,最突出的组合是引起血清素综合征的药物或β1受体阻滞剂与维拉帕米或地尔硫䓬的组合。在具有药代动力学机制的病例中,一半的病例涉及地高辛与维拉帕米的组合。在三分之一的可能ADI病例中,法医病理学家已将所研究的化合物列为潜在的或导致死亡的原因,尽管这些药物在ADI中的具体作用很少被认识到。